Abstract 5300: Clinical utility of whole genome sequencing for upfront risk stratification in AML and MDS patients
Kerry Fitzgerald(LabCorp (United States)), Taylor J. Jensen(LabCorp (United States)), Eric A. Severson(Brigham and Women's Hospital), Marcia Eisenberg(LabCorp (United States)), Traci Pawlowski(Illumina (United States)), JOHN R. HOWITT(LabCorp (United States)), Jake Humphrey(LabCorp (United States)), Brian Caveney(LabCorp (United States)), Jenny Brouckaert(Illumina (United States)), Xiaojun Guan(LabCorp (United States)), Eyad Almasri, Amanda Williamson(LabCorp (United States)), Yuanyu Cao(LabCorp (United States)), Dennis D. Krutkin(LabCorp (United States)), James Han(Illumina (United States)), Grant Hogg(LabCorp (United States)), Jonathan Williams(LabCorp (United States)), Pratheesh Sathyan(Illumina (United States)), Tong Liu(LabCorp (United States)), S. Ramkissoon(LabCorp (United States))
Cited by 0
Related Papers
Changes in circulating microRNA levels associated with prostate cancer
|British Journal of Cancer|2012|717
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
|Cancer Cell|2021|453
Identification of genetic variants using bar-coded multiplexed sequencing
|Nature Methods|2008|305
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
|The Lancet Respiratory Medicine|2022|128
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
|The Lancet Respiratory Medicine|2022|127